NR4A1 and cancer: Studies in this laboratory initially identified 1,1-bis(3′-indolyl)-1-(p-hydroxyphenyl)methane (CDIM8) and the 4-carboxymethyl phenyl analog as NR4A1 ligands that act as antagonists and inhibit NR4A1-dependent pro-oncogenic pathways and genes in breast and other cancer cell lines [18,19,20,21,22,23,24].